The Lancet Oncology in conversation with

Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer

Mon, 27 Apr 2026 23:30:00 +0200

Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years.

Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00014-8/fulltext

James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study

Tue, 31 Mar 2026 01:00:00 +0200

Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).

Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00762-4/fulltext

Tell us what you thought about this episode

Medical imaging and theranostics are revolutionising how we diagnose, treat, and understand disease. To meet this moment, The Lancet group is happy to announce the launch of, The Lancet Medical Imaging and Theranostics.

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Ali Landman on the European Congress of Radiology 2026

Wed, 18 Mar 2026 00:00:00 +0100

Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlights in oncological imaging from the European Congress of Radiology in Vienna, March 4-8, 2026.

To learn more:
European Congress of Radiology: https://www.myesr.org/congress/

The Lancet Medical Imaging & Theranostics: https://www.thelancet.com/medical-imaging-theranostics

For presubmission enquiries and other questions email imaging@lancet.com

To submit your manuscript: https://www2.cloud.editorialmanager.com/thelancetimaging/default2.aspx

Join The Lancet Medical Imaging & Theranostics’ editorial team for a Lancet Webinar dedicated to helping you publish with The Lancet Medical Imaging & Theranostics https://hubs.li/Q042sbn40

Find us on LinkedIn and Bluesky @lancetimaging.bsky.social

Tell us what you thought about this episode

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Kayleigh Bhangdia on breast cancer GBD study 2023

Mon, 09 Mar 2026 10:00:00 +0100

Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries from 1990 to 2023. Kayleigh sheds light on disparities in breast cancer burden across the globe and forecasts to 2050, and highlights the the most critical areas that future GBD studies should focus on to improve the accuracy, relevance, and impact of breast cancer estimates worldwide.

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00730-2/fulltext

Tell us what you thought about this episode

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Dylan Graetz and Erica Kaye on qualitative research in oncology

Tue, 03 Feb 2026 00:00:00 +0100

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz (Department of Oncology and Department of Global Pediatric Medicine, St Jude Children’s Research Hospital) and Dr Erica Kaye (Department of Oncology, St Jude Children’s Research Hospital) to discuss qualitative in oncology.

Read the full Reviews:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00669-2 for The Power of Words: Evaluating the Role of Qualitative Methods in Cancer Research
and
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00670-9 for Expert Recommendations for the Conduct and Appraisal of Qualitative Research in Oncology

and the reviews in Lancet Haematology 2026 https://doi.org/10.1016/S2352-3026(25)00321-7
and eClinicalMedicine https://doi.org/10.1016/j.eclinm.2025.103736

Tell us what you thought about this episode

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers

Tue, 30 Dec 2025 00:00:00 +0100

Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak (Division of Cancer Prevention and Control, The Ohio State University) and Dr Marissa Baker (Department of Environmental & Occupational Health Science, University of Washington School of Public Health) to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA.

Read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00593-5/fulltext

Tell us what you thought about this episode

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3

Tue, 25 Nov 2025 11:00:00 +0100

Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.

Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltext

Tell us what you thought about this episode

You can visit https://www.thelancet.com/medical-imaging-theranostics to learn more.

Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission

Mon, 03 Nov 2025 00:00:00 +0100

Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.

Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology Commission

And comment: Re-establishing human-centred care

Tell us what you thought about this episode

Matthias Preusser on the phase 2 TUXEDO-3 trial

Tue, 28 Oct 2025 00:00:00 +0100

Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer.

Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patients with active brain metastases to clinical trials is so important, and where the field is going next.

Click here to read the full article: Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial

Click here to read the full article: Patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial

Tell us what you thought about this episode

Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer

Tue, 30 Sep 2025 00:00:00 +0200

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue.

Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based chemotherapy. SunRISe-4 is a randomised, open-label, phase 2 trial being conducted at 109 investigative centres in ten countries worldwide, and aims to evaluate the safety and efficacy of neoadjuvant TAR-200 plus cetrelimab (anti-PD-1) versus cetrelimab monotherapy in this disease setting.

They discuss the unique features of the TAR-200 localised sustained delivery system for gemcitabine, the key findings from the SunRISe4-trial trial, and what the future implications of the findings are in terms of better treatment options for patients with bladder cancer.

Read the full article:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00358-4/abstract?dgcid=buzzsprout_icw_podcast_September_25_lanonc

Tell us what you thought about this episode

Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

Tue, 02 Sep 2025 22:00:00 +0200

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas.

In these two cohort studies, the authors analyse the expression of TERT and TERT promoter mutations in meningiomas, assess their association with patient outcomes, and discuss the potential implications for patient management and the classification of these tumours.

You can read the two Articles here:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00267-0/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanonc

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00422-X/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanonc

Tell us what you thought about this episode

Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer

Tue, 29 Jul 2025 00:00:00 +0200

Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Dr Jinming Li, from the Department of Colorectal Surgery, Fudan University Shanghai Cancer Centre, Shanghai, China to discuss his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer.

Read the full article:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00239-6?dgcid=buzzsprout_icw_podcast_July_25_lanonc

Tell us what you thought about this episode

Abdalla Awidi on cancer control in the Middle East

Thu, 12 Jun 2025 00:00:00 +0200

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle East Series. The Series comprises five papers from regional experts who discuss the current outlook for cancer in the Middle East and future developments.

See the whole Series here:

https://www.thelancet.com/series-do/cancer-control-in-middle-east?dgcid=buzzsprout_icw_podcast_lanonccanceremro25_lanonc

Watch the Series video here: https://youtu.be/t3AGdouXpqg

Tell us what you thought about this episode

ASCO 2025 Debrief

Wed, 11 Jun 2025 12:00:00 +0200

Katherine Gourd, Acting Deputy Editor at The Lancet Oncology, and Vania Wisdom, Senior Executive Editor at The Lancet and the journal's Oncology Ambassador, join Leon Terner to share some of their experiences, impressions and highlights from this year's American Society of Clinical Oncology (ASCO) conference.

If you haven't already, be sure to listen to Vania's pre-ASCO predictions podcast here: https://www.buzzsprout.com/882697/episodes/17233167

Articles discussed in this podcast episode include:

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00287-6/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo

Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01040-2/fulltext?dgcid=buzzsprout_icw_podcast_asco2025_lanonc_tlo

#asco2025

Tell us what you thought about this episode

Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial)

Thu, 29 May 2025 00:00:00 +0200

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial. EBIN was an open-label, randomised, controlled, phase 2 trial conducted at 37 centres in eight European countries, and aimed to investigate the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations.

They discuss the disease burden of advanced melanoma with BRAF mutations, the key findings from the EBIN trial, and the future implications of the study findings, especially for a select sub-population of patients with advanced melanoma.

Read the full article:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00133-0/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lanonc

Tell us what you thought about this episode

Richard Bryant on transperineal vs transrectal biopsy for prostate cancer

Thu, 01 May 2025 00:00:00 +0200

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial.

This extensive UK-based randomised controlled trial compares the use of local anaesthetic ultrasound-guided transperineal biopsy with the traditional transrectal biopsy approach for diagnosing prostate cancer. They analyse the key findings of the trial, including the detection rates of clinically significant prostate cancer, infection risks, patient experiences, and the potential implications for clinical practice and health policy.

Read the full article:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00100-7/fulltext?dgcid=buzzsprout_tlv_podcast_30-04-25_lanonc

Tell us what you thought about this episode

Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

Tue, 01 Apr 2025 00:00:00 +0200

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.

Read the full article:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Ariana Znaor on cancer surveillance in the Eastern Mediterranean region

Tue, 04 Mar 2025 00:00:00 +0100

Ariana Znaor (Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France) discusses her Review on cancer surveillance in the Eastern Mediterranean Region: a 10-year IARC-WHO EMRO collaboration.

Tell us what you thought about this episode

Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials

Tue, 04 Feb 2025 00:00:00 +0100

Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials.

Tell us what you thought about this episode

Yannick Romero on the changing landscape of national cancer control plans

Fri, 03 Jan 2025 00:00:00 +0100

Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00405-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries

Tue, 03 Dec 2024 00:00:00 +0100

Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries.

Read the full Series:
https://www.thelancet.com/series/cancer-care-in-saarc-countries?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

Wed, 30 Oct 2024 13:00:00 +0100

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.

Read the full Articles here:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00502-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00503-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

Tue, 01 Oct 2024 00:00:00 +0200

Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.

Read the full Article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00264-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

Mon, 30 Sep 2024 16:00:00 +0200

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.

Read the Commission:
https://www.thelancet.com/commissions/radiotherapy-theranostics?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

Wed, 28 Aug 2024 00:00:00 +0200

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00380-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Emmy Boerrigter on dose selection of novel anticancer drugs

Tue, 30 Jul 2024 00:00:00 +0200

Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00134-7?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations

Tue, 25 Jun 2024 00:00:00 +0200

Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints.

Tell us what you thought about this episode

Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment

Wed, 29 May 2024 00:00:00 +0200

Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it.

Tell us what you thought about this episode

James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean

Tue, 30 Apr 2024 00:00:00 +0200

Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagnosed with cancer from compounding disasters.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00071-8?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials

Tue, 09 Apr 2024 00:00:00 +0200

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00040-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Maria Kyrgiou on innovations in gynaecological cancers and global disparities

Fri, 08 Mar 2024 00:00:00 +0100

In a special episode on International Women's Day 2024, we speak with Dr Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care.

Tell us what you thought about this episode

Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers

Tue, 27 Feb 2024 00:00:00 +0100

Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia.

Tell us what you thought about this episode

Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer

Tue, 30 Jan 2024 00:00:00 +0100

Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00638-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma

Wed, 03 Jan 2024 00:00:00 +0100

Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.

Tell us what you thought about this episode

Neerja Bhatla on a new quadrivalent HPV vaccine

Wed, 29 Nov 2023 15:00:00 +0100

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00480-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery

Thu, 02 Nov 2023 00:00:00 +0100

Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global cancer surgery: pragmatic solutions to improve cancer surgery outcomes worldwide.

Tell us what you thought about this episode

Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma

Wed, 01 Nov 2023 00:00:00 +0100

Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.

Read the full Policy Review:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00453-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Wanda Cui on measuring ovarian toxicity

Tue, 03 Oct 2023 11:00:00 +0200

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00390-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Ticiana Leal on Tumour Treating Fields

Fri, 01 Sep 2023 16:00:00 +0200

Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00344-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA

Wed, 02 Aug 2023 10:00:00 +0200

Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00293-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma

Tue, 04 Jul 2023 00:00:00 +0200

Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00246-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Madeline Pe on the SISAQOL initiative

Thu, 01 Jun 2023 00:00:00 +0200

Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00157-2/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Kadia Petricca and Joyce Kambugu on access to essential cancer medicines for children

Wed, 03 May 2023 00:00:00 +0200

Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00072-4/fulltext?dgcid=buzzsprout_icw_podcast_lanonc_lancet

Tell us what you thought about this episode

Mark Lythgoe on UK oncology drug approval after Brexit

Tue, 28 Mar 2023 00:00:00 +0200

Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".

Tell us what you thought about this episode

Janet Brown on the phase 2/3 STAR trial

Tue, 28 Feb 2023 14:00:00 +0100

Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.

Read the full article:
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR)

Tell us what you thought about this episode

Valerie Speirs on biomarkers in male breast cancer

Tue, 31 Jan 2023 00:00:00 +0100

Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer.

Read the full article:
Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer

Tell us what you thought about this episode

Sameer Bakhshi on sex disparities in childhood cancer in India

Wed, 04 Jan 2023 00:00:00 +0100

Prof Sameer Bakhshi, (All India Institute of Medical Sciences, New Delhi, India) discusses his Article on sex disparities in childhood cancer in India.

Read the full article:
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis

Tell us what you thought about this episode

Shankar Siva on radiotherapy for primary renal cell carcinoma

Tue, 29 Nov 2022 00:00:00 +0100

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Read the full article:
5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma

Tell us what you thought about this episode

Mark Lawler and Richard Sullivan on the European Groundshot

Wed, 16 Nov 2022 00:00:00 +0100

Mark Lawler (Queen’s University Belfast, Belfast, UK) and Richard Sullivan (Kings College London, London, UK) discuss the European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission.

Tell us what you thought about this episode

Samar Alhomoud on challenges for cancer control in the Gulf region

Tue, 01 Nov 2022 00:00:00 +0100

Samar Alhomoud (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) discusses her review on progress and remaining challenges for cancer control in the Gulf Cooperation Council.

Read the full article:
Progress and remaining challenges for cancer control in the Gulf Cooperation Council

Tell us what you thought about this episode

Inge Marie Svane on mRNA vaccines for cancer treatment

Tue, 27 Sep 2022 11:00:00 +0200

Inge Marie Svane (Copenhagen University Hospital, Copenhagen, Denmark) discusses her Review on clinical advances and ongoing trials on mRNA vaccines for cancer treatment.

Read the full Review:
Clinical advances and ongoing trials on mRNA vaccines for cancer treatment

Tell us what you thought about this episode

Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer

Wed, 31 Aug 2022 00:00:00 +0200

Eline Giraud and Elise Smolders from the (Radboud University Medical Center, Nijmegen, Netherlands) discuss their Review on QT interval prolongation potential of anticancer and supportive drugs.

Read the full Review:
The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview

Tell us what you thought about this episode

Ignace Vergote and Maria Kyrgiou on gynaecological cancers

Tue, 26 Jul 2022 00:00:00 +0200

Ignace Vergote (Belgium and Luxembourg Gynaecological Oncology Group, Leuven, Belgium) and Maria Kyrgiou (Imperial College London, London, UK) discuss their Series papers on gynaecological cancers.

Visit the Series hub:
Gynaecological cancers

Tell us what you thought about this episode

David J Pinato on SARS-CoV-2 omicron outcomes among patients with cancer

Thu, 30 Jun 2022 11:00:00 +0200

David J Pinato (Imperial College London, London, UK) discusses the OnCovid registry study on the outcomes of the SARS-CoV-2 omicron variant outbreak among patients with cancer in Europe.

Read the full article:
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe

Tell us what you thought about this episode

Wilfred Ngwa, Beatrice Wiafe-Addai, and David Kerr on cancer in sub-Saharan Africa

Tue, 10 May 2022 00:00:00 +0200

Wilfred Ngwa (Harvard Medical School, Boston, MA, USA; Johns Hopkins University, Baltimore, MD, USA; ICT University, Yaounde, Cameroon), Beatrice Wiafe-Addai (Peace and Love Hospital, Kumasi, Ghana), and David Kerr (University of Oxford, Oxford, UK) discuss the Lancet Oncology Commission on cancer in sub-Saharan Africa.

Tell us what you thought about this episode

Georgios Lyratzopoulos on emergency presentation

Thu, 28 Apr 2022 16:00:00 +0200

Georgios Lyratzopoulos (Institute of Epidemiology & Health Care at University College London, London, UK) discusses his population-based study on risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission.

Read the full article:
Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation)

Tell us what you thought about this episode

Lisa Iezzoni on disabilities and cancer, and Jordan Marchak on mental health problems in young cancer survivors

Tue, 29 Mar 2022 11:00:00 +0200

Lisa Iezzoni (Massachusetts General Hospital, Boston, MA, USA) discusses her Series paper on disabilities and cancer and Jordan Marchak (Children’s Healthcare of Atlanta, Atlanta, GA, USA) discusses her Review on surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors.

Read the full articles:
Cancer detection, diagnosis, and treatment for adults with disabilities

Recommendations for the surveillance of mental health problems in childhood, adolescent, and young adult cancer survivors

Tell us what you thought about this episode

Rosie Bradley on early-stage breast cancer treatment

Tue, 01 Mar 2022 00:00:00 +0100

Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.

Read the full article:
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression

Tell us what you thought about this episode

Yi-Long Wu and Caicun Zhou on non-small-cell lung cancer

Tue, 01 Feb 2022 16:00:00 +0100

Prof Yi-Long Wu (Guangdong Lung Cancer Institute, Guangzhou, China) and Prof Caicun Zhou (Shanghai Pulmonary Hospital, Shanghai, China) discuss the GEMSTONE 301 and GEMSTONE 302 trials on sugemalimab versus placebo in non-small-cell lung cancer.

Read the full articles:
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301)

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302)

Tell us what you thought about this episode

Rebecca Fitzgerald on Barrett’s oesophagus surveillance

Tue, 01 Feb 2022 00:00:00 +0100

Rebecca Fitzgerald (University of Cambridge, Cambridge, UK) discusses her Article on the use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance.

Read the full article:
Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance

Tell us what you thought about this episode

Elysia Alvarez on adolescent and young adult cancer

Thu, 30 Dec 2021 00:00:00 +0100

Elysia Alvarez (UC Davis Comprehensive Cancer Center, Sacramento, USA) discusses her Article on the analysis of the global burden of adolescent and young adult cancer in 2019.

Read the full article:
The global burden of adolescent and young adult cancer in 2019

Tell us what you thought about this episode

Aju Mathew on cancer care in India

Tue, 30 Nov 2021 00:00:00 +0100

Aju Mathew (Malankara Orthodox Syrian Church Medical College and Hospital, Kerala, India) discusses his Review on financial toxicity in cancer care in India.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00468-X/fulltext

Tell us what you thought about this episode

David Pinato on cancer patients who recovered from SARS-CoV-2 infection

Thu, 04 Nov 2021 12:00:00 +0100

David Pinato (Imperial College London, Hammersmith Hospital, London, UK) discusses his Article on prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection.

Read the full paper: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00573-8/fulltext

Tell us what you thought about this episode

James Glasbey on the effect of lockdowns on cancer surgery

Tue, 02 Nov 2021 00:00:00 +0100

James Glasbey (UK NIHR Global Health Research Unit on Global Surgery, University of Birmingham, Birmingham, UK) discusses his Article on the effect of COVID-19 pandemic lockdowns on planned cancer surgery.

Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00493-9/fulltext

Tell us what you thought about this episode

Manju Sengar and Christopher Booth on essential cancer drugs

Tue, 28 Sep 2021 00:00:00 +0200

Manju Sengar (Tata Memorial Centre, India) and Christopher Booth (Queen’s University Cancer Research Institute, Canada) discuss their Article on the comparison between cancer drugs deemed essential by oncologists and those included in the WHO Essential Medicines List.

Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00463-0/fulltext

Tell us what you thought about this episode

Susannah Stanway, Richard Cowan, Danielle Rodin, and Miriam Mutebi on helping with cancer control in LMICs

Wed, 01 Sep 2021 00:00:00 +0200

Susannah Stanway (UK Global Cancer Network), Richard Cowan (Christie NHS Foundation Trust, UK), Danielle Rodin (Princess Margaret Cancer Centre, Canada), and Miriam Mutebi (Aga Khan University Hospital, Kenya) discuss the Global Cancer Control Networks Series on how high-income countries, particularly the UK and Canada, can help with cancer control in low-income and middle-income countries.

Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00374-0/fulltext

Tell us what you thought about this episode

Harriet Rumgay on the burden of cancer attributable to alcohol

Sat, 31 Jul 2021 00:00:00 +0200

Harriet Rumgay (International Agency for Research on Cancer, France) discusses the recent global burden of cancer in 2020 attributable to alcohol consumption study.

Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00279-5/fulltext

Tell us what you thought about this episode

Rafael Cardoso and Hermann Brenner on colorectal cancer

Tue, 29 Jun 2021 00:00:00 +0200

Rafael Cardoso and Hermann Brenner (German Cancer Research Center, Heidelberg, Germany) discuss their recent paper on colorectal cancer incidence, mortality, and stage distribution in Europe.

Read the full paper:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00199-6/fulltext

Tell us what you thought about this episode

Takayuki Yoshino on the DESTINY-CRC01 trial

Wed, 02 Jun 2021 00:00:00 +0200

Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00086-3/fulltext

Tell us what you thought about this episode

Roberto Orecchia on the ELIOT trial

Thu, 29 Apr 2021 00:00:00 +0200

Roberto Orecchia (European Institute of Oncology IRCCS) discusses the ELIOT trial on intraoperative irradiation for early breast cancer.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00080-2/fulltext

Tell us what you thought about this episode

Hedvig Hricak, Andrew Scott, Rifat Atun, and May Abdel-Wahab on nuclear medicine

Wed, 31 Mar 2021 12:00:00 +0200

Hedvig Hricak (Memorial Sloan Kettering Cancer Center), Andrew Scott (Olivia Newton-John Cancer Research Institute), Rifat Atun (Harvard TH Chan School of Public Health), and May Abdel-Wahab (International Atomic Energy Agency) discuss the latest Lancet Oncology’s Commission on Medical Imaging and Nuclear Medicine.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30751-8/fulltext

Tell us what you thought about this episode

Ariana Znaor on breast and cervical cancer in the former Soviet Union

Tue, 02 Mar 2021 00:00:00 +0100

Ariana Znaor, International Agency for Research on Cancer, discusses her Article on breast and cervical cancers stage distributions in ten newly independent states of the former Soviet Union.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30674-4/fulltext

Tell us what you thought about this episode

Sathira Perera on global cancer surgery

Fri, 22 Jan 2021 00:00:00 +0100

Sathira Perera (University of New South Wales, Australia) discusses his (and colleagues) Articles on the global use of cancer surgery.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30675-6/fulltext

Tell us what you thought about this episode

Short-course radiotherapy for advanced rectal cancer

Mon, 04 Jan 2021 01:00:00 +0100

Geke Hospers (University Medical Center Groningen, The Netherlands) discusses the RAPIDO trial Article published in The Lancet Oncology.

Tell us what you thought about this episode

The crucial role of oncology nurses in cancer care

Tue, 17 Nov 2020 00:00:00 +0100

Annie Young (University of Warwick, UK) and Julia Challinor (University of California San Francisco, USA) present their two-paper Series on Oncology Nursing.

Tell us what you thought about this episode

The effect of climate change on cancer control

Tue, 03 Nov 2020 00:00:00 +0100

Robert Hiatt (University of California San Francisco, USA) discusses his and Naomi Beyeler’s (same University) Review on climate change and cancer.

Tell us what you thought about this episode